Clinical trial · Interventional
Combination Chemotherapy in Treating Women With Stage III Breast Cancer
MULTIMODALITY TREATMENT STRATEGY FOR STAGE III BREAST CANCER
NCT00002696CI-TRIAL-00011547suspendedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Randomized phase III trial to compare cyclophosphamide, doxorubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in treating women with stage III breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (10)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| adjuvant therapy | Procedure | — | UNRESOLVED |
| CAF regimen | Drug | — | UNRESOLVED |
| CMF regimen | Drug | — | UNRESOLVED |
| conventional surgery | Procedure | — | UNRESOLVED |
| cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| doxorubicin hydrochloride | Drug | Doxorubicin | ALIAS |
| fluorouracil | Drug | Fluorouracil | ALIAS |
| methotrexate | Drug | Methotrexate | ALIAS |
| neoadjuvant therapy |
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 21 Years
- Maximum age
- 75 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed stage III breast cancer * Measurable disease * No inflammatory breast cancer * No synchronous bilateral breast cancer * Hormone receptor status: * Not specified PATIENT CHARACTERISTICS: Age: * 21 to 75 Sex: * Female Menopausal status: * Not specified Performance status: * ECOG 0-1 OR * Zubrod 0-1 Life expectancy: * More than 12 weeks Hematopoietic: * WBC greater than 4,000/mm\^3 * Platelet count greater than 100,000/mm\^3 Hepatic: * Bilirubin less than 1.25 times upper limit of normal (ULN) * AST less than 1.25 times ULN Renal: * Creatinine clearance greater than 70 mL/min Cardiovascular: * No angina pectoris * No significant arrhythmia requiring therapy * No bilateral bundle branch block * No congestive heart failure * No myocardial infarction Other: * No medical or psychiatric disease that would preclude study therapy * No other malignancy except adequately treated nonmelanomatous skin cancer or carcinoma in situ of the cervix * Not pregnant PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * Not specified Endocrine therapy: * Not specified Radiotherapy: * No prior radiotherapy Surgery: * No prior surgery except incisional biopsy or fine-needle aspiration Other: * No prior systemic therapy * No concurrent caffeine or alcohol
References
Publications (0)
Data not yet available
No reference posted for this study.